TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23340188

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 390

Group type: COMPARATOR
Intervention: Complicated appendicitis
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Post-operative length of stay (LOS)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Readmission
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Non-satisfactory outcomes
Number of subjects: 390
Study: 23340271

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Conventional medical therapies (CMTs)
Number of subjects: 647
Study: 23340531

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100 - 250 mg bid)
Number of subjects: 4
Study: 23340882

Group type: EXPERIMENTAL
Intervention: PCI-CLI group (111 patients with CLI)
Number of subjects: 764

Group type: COMPARATOR
Intervention: PCI-only group (653 patients without CLI)
Number of subjects: 764
Study: 23341491

Group type: EXPERIMENTAL
Intervention: iv pulsatile GnRH (75 ng/kg per bolus)
Number of subjects: 37
Study: 23341526

Group type: EXPERIMENTAL
Intervention: Erlotinib plus whole-brain radiation therapy (WBRT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erlotinib plus WBRT
Number of subjects: 40
Study: 23342272

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 14
Study: 23343427

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox®) 400 mg once daily for a mean duration of 6.4 ± 1.9 days
Number of subjects: 2536

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (Avelox®)
Number of subjects: 2536
Study: 23344123

Group type: EXPERIMENTAL
Intervention: Patients receiving neuromuscular block reversal agents (66.6% of patients; neostigmine in 97%)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Patients not receiving neuromuscular block reversal agents
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patients receiving propofol
Number of subjects: 350

Group type: COMPARATOR
Intervention: Patients receiving sevoflurane
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patients receiving cisatracurium
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patients receiving vecuronium
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patients receiving atracurium
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Patients receiving rocuronium
Number of subjects: 350
Study: 23344286

Group type: EXPERIMENTAL
Intervention: Pravastatin (dosage and duration not specified)
Number of subjects: 0
Study: 23344397

Group type: EXPERIMENTAL
Intervention: Balloon tamponade combined with medical management
Number of subjects: 1

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 1
Study: 23344409

Group type: EXPERIMENTAL
Intervention: Monitoring for malignancy and consideration of hysterectomy after childbearing is completed.
Number of subjects: 1
Study: 23345012

Group type: EXPERIMENTAL
Intervention: Executive cognitive function (ECF)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Physical activity and exercising with parents
Number of subjects: 1005
Study: 23348202

Group type: EXPERIMENTAL
Intervention: i.v. fluid (15 ml kg(-1) in 30 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SVV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PVI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Eadyn
Number of subjects: 30
Study: 23348203

Group type: EXPERIMENTAL
Intervention: Subgluteal sciatic nerve block with 20 ml of ropivacaine 4.75 mg ml(-1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (non-diabetic patients)
Number of subjects: 72
Study: 23348658

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) providing 3.3-4.2 MJ/day to replace all meals
Number of subjects: 938
Study: 23348820

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical Depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep Apnea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thyroid Disease
Number of subjects: 0
Study: 23348979

Group type: EXPERIMENTAL
Intervention: MACOCHA score (simplified score for difficult intubation)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: MACOCHA score (validation cohort)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Difficult intubation
Number of subjects: 1000
Study: 23349326

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stromal cells (MSCs) - 1 million cells per kilogram, two intravenous infusions
Number of subjects: 6
Study: 23349346

Group type: EXPERIMENTAL
Intervention: N-terminal fragment of proBNP (Nt-proBNP)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients followed for AS-related events
Number of subjects: 361
Study: 23349878

Group type: EXPERIMENTAL
Intervention: MVA vaccine
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 23349902

Group type: EXPERIMENTAL
Intervention: Uric acid (UA) levels during malaria episode
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: sICAM-1 levels during malaria episode
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: sVCAM-1 levels during malaria episode
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: sE-Selectin levels during malaria episode
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: sTM levels during malaria episode
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Correlation of UA levels with parasite density in UM
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Correlation of sICAM-1 levels with UA levels in UM
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Correlation of sTM levels with UA levels in UM
Number of subjects: 555
Study: 23350893

Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 32871

Group type: COMPARATOR
Intervention: Low education category
Number of subjects: 32871

Group type: COMPARATOR
Intervention: Higher education category
Number of subjects: 32871
Study: 23351121

Group type: EXPERIMENTAL
Intervention: Steroid treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical and genetic factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Socio-demographic, environmental, and clinical risk factors
Number of subjects: 0
Study: 23351590

Group type: EXPERIMENTAL
Intervention: Escitalopram (single dose)
Number of subjects: 12
Study: 23351618

Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% patch) for 30 minutes
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: NGX-4010 (capsaicin 8% patch) for 60 minutes
Number of subjects: 482

Group type: COMPARATOR
Intervention: Low-concentration control patch (capsaicin 0.04% w/w)
Number of subjects: 482
Study: 23352199

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 311

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 311

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 311

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: High doses of valproate
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Periconceptional folate
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Lamotrigine group
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Valproate group
Number of subjects: 311
Study: 23352429

Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 vaccine (120 μg doses at 0, 1, and 6 months)
Number of subjects: 60
Study: 23352786

Group type: EXPERIMENTAL
Intervention: Minimum Lumen Area (MLA) <3.07 mm²
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: MLA <2.4 mm²
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: MLA <2.7 mm²
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: MLA <3.6 mm²
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: FFR
Number of subjects: 350
Study: 23353804

Group type: EXPERIMENTAL
Intervention: Clinician assessment of oral changes according to NIH criteria
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Patient-reported symptom and quality-of-life measures
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Clinician and patient assessments of oral changes
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Measurement changes predictive of perceived change
Number of subjects: 458
Study: 23354509

Group type: EXPERIMENTAL
Intervention: Successful CPAP therapy (n = 16)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unsuccessful CPAP therapy (n = 8)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No OSA (n = 16)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: HFC ≥ 50 %
Number of subjects: 50
Study: 23354923

Group type: EXPERIMENTAL
Intervention: In vivo sentinel lymph node procedure with isosulfan blue 1 %
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Intraoperative visualization of blue lymphatic vessels
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Higher numbers of SLN identified
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: pN2 stage
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Lower body mass index (BMI)
Number of subjects: 174
Study: 23355122

Group type: EXPERIMENTAL
Intervention: Physical activity (mean step count = 8,575 ± 3,191)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Presence of 3 or more MetS traits
Number of subjects: 223
Study: 23355669

Group type: EXPERIMENTAL
Intervention: Point-of-decision prompts on hospital elevator doors promoting stair use
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Point-of-purchase prompts in the hospital restaurant promoting reduced-salt soup
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Point-of-purchase prompts in the hospital restaurant promoting lean croissants
Number of subjects: 11000

Group type: EXPERIMENTAL
Intervention: Reversal of the accessibility and availability of diet margarine and butter in the hospital restaurant
Number of subjects: 11000
Study: 23355673

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg daily for 42 days
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily for 42 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nadroparin 0.3 ml subcutaneously for 42 days
Number of subjects: 150
Study: 23356818

Group type: EXPERIMENTAL
Intervention: Non-European races (black Africans, Chinese, Japanese)
Number of subjects: 2580

Group type: EXPERIMENTAL
Intervention: Chinese
Number of subjects: 2580

Group type: EXPERIMENTAL
Intervention: Japanese
Number of subjects: 2580

Group type: EXPERIMENTAL
Intervention: Black Africans
Number of subjects: 2580

Group type: COMPARATOR
Intervention: Europeans
Number of subjects: 2580
Study: 23357569

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 2511
Study: 23358617

Group type: EXPERIMENTAL
Intervention: Darbepoetin (DAR) 500 μg once every 2 weeks for 12 weeks
Number of subjects: 99
Study: 23358640

Group type: EXPERIMENTAL
Intervention: Uncomplicated malaria
Number of subjects: 1933

Group type: EXPERIMENTAL
Intervention: Severe malaria
Number of subjects: 1933

Group type: EXPERIMENTAL
Intervention: Cerebral malaria, hypoxia, severe thrombocytopenia, leukocytosis, lactic acidosis
Number of subjects: 1933

Group type: EXPERIMENTAL
Intervention: Anemia, splenomegaly, leukocytosis
Number of subjects: 1933

Group type: EXPERIMENTAL
Intervention: Death, severe thrombocytopenia, lactic acidosis, cerebral malaria, hypoxia, hypoglycemia, hyper-parasitemia
Number of subjects: 1933
Study: 23358817

Group type: EXPERIMENTAL
Intervention: Computed tomography coronary angiography (CTCA)
Number of subjects: 1000
Study: 23359181

Group type: EXPERIMENTAL
Intervention: Panitumumab (9 mg/kg) followed by Irinotecan (350 mg/m²) every 21 days
Number of subjects: 53
Study: 23359360

Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 57
Study: 23359362

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145
Study: 23359515

Group type: EXPERIMENTAL
Intervention: CHIT1 duplication
Number of subjects: 40
Study: 23360920

Group type: EXPERIMENTAL
Intervention: Liver transplantation for nonresectable CLMs
Number of subjects: 21
Study: 23361157

Group type: EXPERIMENTAL
Intervention: Irish participants
Number of subjects: 324

Group type: COMPARATOR
Intervention: Spanish participants
Number of subjects: 324

Group type: COMPARATOR
Intervention: Icelandic participants
Number of subjects: 324
Study: 23361508

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3-2.0 mg/eye) administered intravitreally (ITV) biweekly or monthly for up to 24 months
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 and 0.5 mg/eye) administered ITV monthly and quarterly
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic analysis
Number of subjects: 674
Study: 23362021

Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM) sessions
Number of subjects: 1650
Study: 23362168

Group type: EXPERIMENTAL
Intervention: Walking desaturation score (0-6)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Walking desaturation score categories (low 0-1, high 2-3, very high 4-6)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Hosmer-Lemeshow goodness-of-fit test
Number of subjects: 673
Study: 23362308

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of progenitor cells
Number of subjects: 775
Study: 23363496

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: Cefdinir
Number of subjects: 2767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2767
Study: 23364010

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT)
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA) measures
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Anthropometric measures
Number of subjects: 1346
Study: 23364011

Group type: EXPERIMENTAL
Intervention: 25(OH)D deficiency (<10 ng/mL)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: 25(OH)D insufficiency (10.0-19.9 ng/mL)
Number of subjects: 1080

Group type: COMPARATOR
Intervention: 25(OH)D sufficiency (≥20 ng/mL)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Overall incidence of T2D
Number of subjects: 1080
Study: 23364320

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional NSAID therapy
Number of subjects: 0
Study: 23369084

Group type: EXPERIMENTAL
Intervention: 1.20 mm diameter angioplasty catheter
Number of subjects: 71
Study: 23369112

Group type: EXPERIMENTAL
Intervention: Demand valve oxygen
Number of subjects: 4

Group type: COMPARATOR
Intervention: Continuous flow oxygen
Number of subjects: 4
Study: 23369230

Group type: EXPERIMENTAL
Intervention: Random capillary glucose (RCG)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: ADA diabetes risk test (DRT)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Skin fluorescence spectroscopy (SFS)
Number of subjects: 398
Study: 23369437

Group type: EXPERIMENTAL
Intervention: Shotgun proteomics analysis of urine samples from patients with acute rejection (AR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Shotgun proteomics analysis of urine samples from age-matched controls
Number of subjects: 12
Study: 23369458

Group type: EXPERIMENTAL
Intervention: Thymoglobulin induction combined with early steroid reduction to 5 mg/day, low dose cyclosporine (C2 target of 600 to 800 ng/ml), and mycophenolic acid (MPA) therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Historical cohort treated with Thymoglobulin induction, conventional doses of cyclosporine and corticosteroids
Number of subjects: 49
Study: 23370048

Group type: EXPERIMENTAL
Intervention: School-based nutrition education interventions
Number of subjects: 8722
Study: 23370203

Group type: EXPERIMENTAL
Intervention: Modified Graeb Score (mGS)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Original Graeb Scale
Number of subjects: 435
Study: 23370503

Group type: EXPERIMENTAL
Intervention: Increased anxiety (measured by HADS-Anxiety score)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Higher levels of depressive symptoms (measured by HADS-Depression score)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Interaction of anxiety and depression
Number of subjects: 148
Study: 23370599

Group type: EXPERIMENTAL
Intervention: 10 μg nebulized iloprost
Number of subjects: 20
Study: 23371395

Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir
Number of subjects: 2398
Study: 23372266

Group type: EXPERIMENTAL
Intervention: 3.5 mg ZST
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 23372270

Group type: EXPERIMENTAL
Intervention: APAP with C-Flex
Number of subjects: 93

Group type: COMPARATOR
Intervention: APAP
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: APAP with A-Flex
Number of subjects: 93
Study: 23372269

Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration and latency
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 191
Study: 23372690

Group type: EXPERIMENTAL
Intervention: Urinary proteomic analysis using iTRAQ labeling and 2D-LC-MS/MS
Number of subjects: 84
Study: 23373567

Group type: EXPERIMENTAL
Intervention: Decompressive laminectomy without fusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Facet angle > 50°
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Disc height > 6.5 mm
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Motion at spondylolisthesis > 1.25 mm
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All 3 risk factors (motion at spondylolisthesis > 1.25 mm, disc height > 6.5 mm, facet angle > 50°)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: No risk factors for instability
Number of subjects: 40
Study: 23374856

Group type: EXPERIMENTAL
Intervention: Pam3CSK4 (specific TLR2/1 ligand)
Number of subjects: 34

Group type: COMPARATOR
Intervention: TLR expression on lung CD8+ T cells
Number of subjects: 34

Group type: COMPARATOR
Intervention: TLR expression on lung CD4+ T cells and CD8+ NKT cells
Number of subjects: 34

Group type: COMPARATOR
Intervention: TLR expression on lung CD56+ NK cells
Number of subjects: 34
Study: 23374970

Group type: EXPERIMENTAL
Intervention: Catheter ablation procedure with high left atrial appendage peak flow velocity (LAV >0.3 m/s)
Number of subjects: 40
Study: 23374979

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT) with 54 Gy and 5-fluorouracil-based regimen
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Positive inguinal node uptake after CRT (positive PET at baseline and 12 weeks)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Patients with positive inguinal node uptake
Number of subjects: 99
Study: 23375202

Group type: EXPERIMENTAL
Intervention: Variants rs3797179 (SRD5A1), rs12473543 (POMC), and rs1501299 (ADIPOQ)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Variants in the FBN3 gene (rs17202517 and rs73503752)
Number of subjects: 997

Group type: EXPERIMENTAL
Intervention: Variant rs727428 in the SHBG gene
Number of subjects: 997

Group type: COMPARATOR
Intervention: Previously identified variants in candidate genes
Number of subjects: 997
Study: 23375329

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of autologous bone marrow concentrate
Number of subjects: 13
Study: 23375478

Group type: EXPERIMENTAL
Intervention: hs-cTnT measurement at 3 hours
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: hs-cTnT diagnostic algorithm
Number of subjects: 306

Group type: COMPARATOR
Intervention: Cumulative survival
Number of subjects: 306
Study: 23375717

Group type: EXPERIMENTAL
Intervention: Weight loss of ≥5% of initial weight
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Weight loss of ≥5% of initial weight at 6 months
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Weight loss at 18 months
Number of subjects: 220
Study: 23375908

Group type: EXPERIMENTAL
Intervention: Breast milk (BM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy formula (SF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cow's milk formula (CMF) and Soy formula (SF)
Number of subjects: 0
Study: 23375926

Group type: EXPERIMENTAL
Intervention: Yoga training (twice-weekly 60-min sessions for 3 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yoga training
Number of subjects: 0
Study: 23376426

Group type: EXPERIMENTAL
Intervention: 1-sample OC Sensor FIT
Number of subjects: 19797

Group type: EXPERIMENTAL
Intervention: 1-sample Magstream FIT
Number of subjects: 19797

Group type: COMPARATOR
Intervention: Hemoccult II guaiac test
Number of subjects: 19797
Study: 23377438

Group type: EXPERIMENTAL
Intervention: Regadenoson (1.44 μg/kg/h) during pVOC
Number of subjects: 27
Study: 23377586

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 37
Study: 23377664

Group type: EXPERIMENTAL
Intervention: GAA peptide-pulsed DCs
Number of subjects: 34

Group type: COMPARATOR
Intervention: ATL-pulsed DC vaccination
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both GAA-DC and ATL-DC
Number of subjects: 34
Study: 23377668

Group type: EXPERIMENTAL
Intervention: Anti-MAGE-A3 TCR-engineered T cells
Number of subjects: 9
Study: 23377993

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in susceptible individuals
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure in non-susceptible individuals
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Healthy smokers
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Non-biased approaches such as proteomics
Number of subjects: 200
Study: 23378284

Group type: EXPERIMENTAL
Intervention: Two 30-μg doses of unadjuvanted, inactivated pH1N1 vaccine 21 days apart
Number of subjects: 127
Study: 23379680

Group type: EXPERIMENTAL
Intervention: FEC60 regimen
Number of subjects: 60